arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

ClearPoint Neuro, Inc.

CLPT
$14.23 ▲ +0.85 (+6.31%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
64 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

ClearPoint Neuro, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $420.5M
Dividend Yield
Revenue Growth 42.9%
Op. Margin -69.9%
ROIC -12.4%
FCF / Share $-0.29
Trailing P/E
Price / Book 22.7x
FCF Yield
Debt / Equity 2.63
info Valuation on last close. End-of-day price, Aug 7, 2026.

64-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$12.13M
↑ +42.9%
Net Income Profit after all expenses
$-9.55M
↓ -58.5%
Operating Margin Operating profit as % of sales
-69.9%
↓ -3.3% 4th
FCF / Share Free cash flow per share
$-0.29
↓ -27.1%
Long-Term Debt Long-term obligations
$49.64M
↑ +1.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
10
Financial Health
18
Cash Quality
63

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 64 quarters